JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID 19 antibody level in hematological patients
Abstract
Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors.
Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA).
Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group.
Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.

Keywords : COVID 19 vaccine, tyrosine kinase inhibitor, chemotherapy, anti-SARS-CoV-2 IgG

Download Article


1. Madariaga A, McMullen M, Sheikh S, et al. COVID-19 Testingin Patients with Cancer: Does One Size Fit All?. Clin Cancer Res.2020;26(18):4737-4742. doi:10.1158/1078-0432.CCR-20-2224
2. Martin M, Guerrero-Zotano A, Montero Á, et al. GEICAM Guidelinesfor the Management of Patients with Breast Cancer During theCOVID-19 Pandemic in Spain. Oncologist. 2020;25(9):e1339-e1345.doi:10.1634/theoncologist.2020-0363
3. World Health Organization. Draft landscape of COVID-19 candidatevaccines. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (Accessed on October20, 2020).
4. Zhou P, Yang XL, Wang XG, et al. Addendum: A pneumonia outbreakassociated with a new coronavirus of probable bat origin. Nature.2020;588(7836):E6. doi:10.1038/s41586-020-2951-z
5. Krammer F. SARS-CoV-2 vaccines in development. Nature.2020;586(7830):516-527. doi:10.1038/s41586-020-2798-3
6. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenicallydrifted influenza by inactivated and live attenuated vaccines. N Engl JMed. 2006;355(24):2513-2522. doi:10.1056/NEJMoa061850
7. Graepel KW, Kochhar S, Clayton EW, Edwards KE. BalancingExpediency and Scientific Rigor in Severe Acute Respiratory SyndromeCoronavirus 2 Vaccine Development. J Infect Dis. 2020;222(2):180-182.doi:10.1093/infdis/jiaa234
8. Centers for Disease Control and Prevention. Updated healthcareinfection prevention and control recommendations in responseto COVID-19 vaccination. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html(Accessed on May 05, 2021).
9. Mark C, Gupta S, Punnett A, et al. Safety of administration ofBNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youthsand young adults with a history of acute lymphoblastic leukemia andallergy to PEG-asparaginase. Pediatr Blood Cancer. 2021;68(11):e29295.doi:10.1002/pbc.29295
10. Shulman RM, Weinberg DS, Ross EA, et al. Adverse Events Reportedby Patients With Cancer After Administration of a 2-Dose mRNACOVID-19 Vaccine. J Natl Compr Canc Netw. 2022;20(2):160-166.doi:10.6004/jnccn.2021.7113
11. Wu JT, La J, Branch-Elliman W, et al. Association of COVID-19Vaccination With SARS-CoV-2 Infection in Patients With Cancer: AUS Nationwide Veterans Affairs Study. JAMA Oncol. 2022;8(2):281-286.doi:10.1001/jamaoncol.2021.5771
12. Mair MJ, Berger JM, Berghoff AS, et al. Humoral Immune Responsein Hematooncological Patients and Health Care Workers WhoReceived SARS-CoV-2 Vaccinations. JAMA Oncol. 2022;8(1):106-113.doi:10.1001/jamaoncol.2021.5437
13. Fendler A, Shepherd STC, Au L, et al. Omicron neutralising antibodiesafter third COVID-19 vaccine dose in patients with cancer. Lancet.2022;399(10328):905-907. doi:10.1016/S0140-6736(22)00147-7
14. Lim SH, Stuart B, Joseph-Pietras D, et al. Immune responses againstSARS-CoV-2 variants after two and three doses of vaccine in B-cellmalignancies: UK PROSECO study. Nat Cancer. 2022;3(5):552-564.doi:10.1038/s43018-022-00364-3
15. Rottenberg Y, Grinshpun A, Ben-Dov IZ, Oiknine Djian E, Wolf DG,Kadouri L. Assessment of Response to a Third Dose of the SARS-CoV-2BNT162b2 mRNA Vaccine in Patients With Solid Tumors UndergoingActive Treatment. JAMA Oncol. 2022;8(2):300-301. doi:10.1001/jamaoncol.2021.6764
16. NCCN: Cancer and COVID-19 Vaccination. Available online:https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66 (Accessed onDecember 01, 2021).
17. American College of Rheumatology. COVID-19 Vaccine ClinicalGuidance Summary for Patients with Rheumatic and MusculoskeletalDiseases. https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf(Accessed on March 04, 2021).
18. Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-termsafety of the BNT162b2 mRNA COVID-19 vaccine in patients withcancer treated with immune checkpoint inhibitors. Lancet Oncol.2021;22(5):581-583. doi:10.1016/S1470-2045(21)00155-8
19. Fang FC, Naccache SN, Greninger AL. The Laboratory Diagnosis ofCoronavirus Disease 2019- Frequently Asked Questions. Clin InfectDis. 2020;71(11):2996-3001. doi:10.1093/cid/ciaa742
20. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion ratesfollowing COVID-19 vaccination among patients with cancer. CancerCell. 2021;39(8):1081-1090.e2. doi:10.1016/j.ccell.2021.06.002
21. Ollila TA, Lu S, Masel R, et al. Antibody Response to COVID-19Vaccination in Adults With Hematologic Malignant Disease. JAMAOncol. 2021;7(11):1714-1716. doi:10.1001/jamaoncol.2021.4381
Article available in :
Volume 1, Issue 1, 2023
Page : 1-4
https://doi.org/10.51271/JCHOR-0001
Article Information
Received : 20 Ara 2022
Accepted : 24 Şub 2023
Published : 26 Şub 2023
Corresponding Author :

İlhami Berber: Department of Hematology, Turgut Ozal Medical Center, İnonu University, Malatya, Turkiye

İ[email protected]
Citation : Kaya A, Berber İ, Kuku İ, et al. Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID-19 antibody level in hematological patients. J Curr Hematol Oncol Res. 2023; 1(1): 1-4

Read: 1534
Cited: 0
Download : 403
_Footer